相关实验视频

Updated: May 16, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

在心房的外部心脏转变期间的活性压缩:随机对照试验的元分析

Hosam I Taha¹, Abubakar Nazir², Ahmed A Ibrahim³

¹Faculty of Medicine, Tanta University, Tanta, Egypt.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

|April 1, 2025

概括

对于心房动,在直流心转动 (DCCV) 期间进行的活跃胸部压缩不会提高成功率,但可能会降低能量需求. 需要进一步的研究来证实这种技术的临床益处.

科学领域:

心脏病学心脏病学
电力生理学电力生理学
医疗器械医疗器械

背景情况:

直流心转 (DCCV) 是心房动的主要治疗方法.
在DCCV期间加入活跃胸部压缩的有效性尚不清楚.

研究的目的:

评估活跃胸部压缩对心脏转变结果在心房的患者的影响.
综合随机对照试验 (RCT) 的证据,以确定DCCV期间主动压缩的有效性.

主要方法:

一个系统的审查和四个RCT的元分析涉及737名患者.
数据是从主要的科学数据库 (PubMed,Scopus,WOS,Embase,Cochrane Library) 中检索出来的.
统计分析使用了风险比率和平均差异,具有95%的置信区间.

主要成果:

活性压缩并没有显著改善整体心脏转变成功 (RR: 1.10; 95% CI [0.96, 1.25]) 或第一次冲击成功 (RR: 1.62; 95% CI [0.94, 2.81]).
在冲击数量或交叉成功率方面没有观察到显著差异.
在活性压缩时,成功的冲击能量显著减少 (MD: -23.97 J; 95% CI [-26.84, -21.10]).

结论:

在DCCV期间,积极的胸部压缩并不能提高心脏转变成功率.
这种技术可能会减少成功心脏转换所需的能量,并可能带来安全益处.
需要进一步的研究来确定减少能源需求的临床意义.

关键词:

节律失常节律失常心房动是心房动的一种.胸部压力胸部压力动脉逆转动脉除.电力反冲击电力反冲击电力反冲击复苏复苏复苏复苏复苏复苏复苏复苏

更多相关视频

Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling

Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling

Published on: April 19, 2024

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

相关概念视频

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Disturbances in Heart Rhythm

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...